Viewing Study NCT07190300

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-26 @ 12:16 PM
Ignite Modification Date: 2026-01-03 @ 11:10 PM
Study NCT ID: NCT07190300
Status: RECRUITING
Last Update Posted: 2025-12-02
First Post: 2025-09-16
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) View
None Enhancer of Zeste Homolog 2 (EZH2) View
None Androgen Receptor (AR) View
None Androgen Receptor Pathway Inhibitors (ARPIs) View
None Prostate-Specific Antigen (PSA) View
None Biochemical Response Rate (BCR) View
None TulmiSTAR-02 View